23:45 , Jul 18, 2019 |  BC Extra  |  Financial News

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures...
18:47 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

Chemically induced knockdown of SMARCA2/4 to treat AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Boehringer Ingelheim GmbH and University of Dundee showed that proteolysis-targeting chimeric molecules (PROTAC) targeting SMARCA2 and SMARCA4 could help treat AML. Chemical optimization guided by crystal structures...
23:12 , Jun 19, 2019 |  BC Extra  |  Company News

Gilead adds targeted degradation via Nurix deal in quest to strengthen growth areas

Just three months after Daniel O'Day took the helm, Gilead has pulled the trigger on adding targeted protein degradation to its modality tool kit in areas it has tagged as growth drivers. Wednesday’s announcement of...
15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
23:58 , Apr 4, 2019 |  BC Week In Review  |  Clinical News

Peloton’s PT2977 leads to partial response rate of 22% in RCC patients

Peloton said once-daily 120 mg PT2977 led to a confirmed partial response rate of 22% among 55 evaluable previously treated patients with advanced renal cell carcinoma in the Phase II portion of a Phase I/II...
19:10 , Feb 22, 2019 |  BC Week In Review  |  Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
23:22 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies identified a selective degrader of ESR1 that could help treat estrogen receptor-positive breast cancer. Chemical synthesis and testing in human estrogen receptor-positive breast cancer lines of analogs of the...
19:51 , Feb 20, 2019 |  BC Extra  |  Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies identified an aryloxytetramethylcyclobutane-based degrader of androgen receptor that could help treat prostate cancer. Chemical synthesis and testing in three prostate cancer cells lines of analogs of a...